Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203093 · ClinicalTrials.gov registry record
Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking
A clinical trial of Healthy and Charcot Marie Tooth Disease, sponsored by New York Stem Cell Foundation Research Institute.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT06203093: Recruiting study of Healthy and Charcot Marie Tooth Disease, sponsored by New York Stem Cell Foundation Research Institute.
NCT06203093 is a study of Healthy and Charcot Marie Tooth Disease that is actively recruiting participants, run by New York Stem Cell Foundation Research Institute. The registered enrollment target is 50 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06203093, a study of Healthy and Charcot Marie Tooth Disease, is actively recruiting participants, sponsored by New York Stem Cell Foundation Research Institute.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Charcot-Marie-Tooth disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use. Through this research, researchers hope to identify future treatments or even cures for Charcot-Marie-Tooth disease.
Conditions Studied
Interventions
- OTHER Biological Sample Collection
Study Locations (1)
New York
- New York Stem Cell Foundation Research Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2025-09-22 |
What NCT06203093 shows while recruiting
NCT06203093 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Biological Sample Collection is the first listed.
NCT06203093 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06203093 about?
NCT06203093 is a clinical study titled "Charcot-Marie-Tooth Disease (CMT) Biological Sample Collection for IPSC Generation and Biobanking". The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Charcot-Marie-Tooth disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, pe...
What is the current status of trial NCT06203093?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2022-09-22. Estimated completion is 2025-09-22.
What conditions does trial NCT06203093 study?
This clinical trial studies the following conditions: Healthy, Charcot Marie Tooth Disease.
What interventions are being tested in trial NCT06203093?
The interventions under investigation include: Biological Sample Collection (OTHER).
Who is sponsoring clinical trial NCT06203093?
This trial is sponsored by New York Stem Cell Foundation Research Institute, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06203093 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06203093's enrollment target sits among peer trials
50 448th of 1090 higher than 618 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
The Modulatory Effect of Female Sex Hormones on Spinal Neuroplasticity
RECRUITING
-
Breathing & Blood Pressure
RECRUITING
-
Neuromodulation-assisted Ego-disengagement: The NEURO-EGO Study Stage 1
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
- NCT01746836 · 50 participants · Phase 2
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI